GSTM1 and cancer: In higher FIT ranges, colonoscopy rates remained high; in the FIT 101-150 (μg Hb/g) group, seven out of 13 patients (53.8%) had colonoscopies, detecting two cancers; and in those with FIT >400 (μg Hb/g), 34 out of 43 patients (79.1%) underwent colonoscopy, identifying 13 cancers (30.2%), making this group the most predictive for malignancy.